Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-28
2006-02-28
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S462000, C549S469000
Reexamination Certificate
active
07005448
ABSTRACT:
The present invention provides novel compounds, compositions containing the compounds of the invention in a pharmaceutically acceptable excipient and methods for using the compositions for lowering intraocular pressure.
REFERENCES:
patent: 5011846 (1991-04-01), Gittos et al.
patent: 5106555 (1992-04-01), Kobayashi et al.
patent: 5290781 (1994-03-01), Espino et al.
patent: 5538974 (1996-07-01), Ogawa et al.
patent: 5652272 (1997-07-01), Ogawa et al.
patent: 5693654 (1997-12-01), Birch
patent: 2003/0092774 (2003-05-01), Parkinson et al.
patent: 0 522 226 (1997-09-01), None
patent: 0 771 563 (2003-01-01), None
patent: WO 92/20333 (1992-11-01), None
patent: WO 97/17345 (1997-05-01), None
patent: WO 00/44737 (2000-08-01), None
Ahmad, “Fluoxetine and Glaucoma,”Annals of Pharmacotherapy, 25:436 (1991).
Barnett et al., “The Presence of Serotonin (5-HT1) Receptors Negatively Coupled to Adenylate Cyclase in Rabbit and Human Iris-Ciliary Processes,”Exp. Eye Res., 57:209-216 (1993).
Chang et al., “Mechanism of the Ocular Hypotensive Action of Ketanserin,”J. of Ocular Pharmacology, 1(2):137-147 (1985).
Chidlow et al., “Characteristics of [3H]5-Hydroxytryptamine Binding to Iris-Ciliary Body Tissue of the Rabbit,”Invest. Ophthal. & Vis. Sci., 36(11):2238-2245 (1995).
Costagliola et al., “Effect of Oral Ketanserin Administration on Intraocular Pressure in Glaucomatous Patients,”Exp. Eye Res.52:507-510 (1991).
Costagliola et al., “Fluoxetine and Administration Increases Intraocular Pressure,”Brt. J. Ophthalmol, 80:678 (1996).
Eglen et al., “The 5-HT7Receptor: Orphan Found,”Trends Pharmacol. Sci,,18:104-7 (1997).
Heidmann et al., “Four 5-Hydroxytryptamine7(5-HT7) Receptor Isoforms in Human and Rat Produced by Alternative Splicing: Species Differences Due to Altered Intron—Exon Organization,”J. of Neurochemistry, 68(4):1372-1381 (1997).
Hoyer et al., “VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin),”Pharmacological Reviews, 46(2):157-203 (1994 ).
Krootila et al., “Effect of Serotonin and Its Antagonist (Ketanserin) on Intraocular Pressure in the Rabbit,”J. of Ocular Pharmacology, 3(4):279-290 (1987).
Mallorga et al., “Characterization of Serotonin Receptors in the Iris + Ciliary Body of the Albino Rabbit,”Current Eye Research6(3):527-532 (1987).
Mano et al., “The Effect of ANPLAG® (Sarpogrelate HCL), New Selective 5-HT2Antagonist on Intraocular Pressure in Glaucoma Patients,”Invest. Orphthal.&Vis. Sci., 36(4): 3322-309 (S719) (1995).
Martin et al., “The Structure and Signalling Properties of 5-HT Receptors: An Endless Diversity?”,Trends Pharmacol. Sci., 19:2-4 (1998).
Martin et al., “Serotonin in Human Aqueous Humor,”Ophthalmol, 95(9):1221-1226 (1998).
Meyer-Bothling et al., “Topical Application of Serotonin or the 5-HT1-Agonist 5-CT Intraocular Pressure in Rabbits,”Invest. Ophthal.&Vis. Sci., 34(10):3035-3042 (1993).
Osborne et al., “Do Beta-Adrenoceptors and Serotonin 5-HT1AReceptors Have Similar Functions in the Control of Intraocular Pressure in the Rabbit,” Ophthalmologica 210:308-314 (1996).
Takenaka et al, “The Effect of ANPLAG® (Sarpogrelate HCL), Novel Selective 5-HT2Antagonist on Intraocular Pressure in Glaucoma Patients,”Invest. Ophthal.&Vis. Sci., 36(4):3390-377 (1995).
Tobin et al., “Evidence for the Presence of Serotonin Receptors Negatively Coupled to Adenylate Cyclase in the Rabbit Iris-Ciliary Body,”J. of Neurochemistry, 53(3):686-691 (1989).
Tobin et al., “Evidence for the Presence of Serotonergic Nerves and Receptors in the Iris-Ciliary Body Complex of the Rabbit,”J. of Neuroscience, 8(10):3713-3721 (1988).
Wang et al., “Effect of 5-methylurapidil, an α1a-adrenergic Antagonist and 5-hydroxytryptamine1aAgonist, on Aqueous Humor Dynamics in Monkeys and Rabbits,”Current Eye Research, pp. 769-775 (Apr. 1997).
Wang et al., “Effect of p-MPPI Hydrochloride (p-MPPI) Applied Before 5-Methylurapidil (5-MU) on Intraocular Pressure (IOP) in Normal Monkeys,”Invest. Ophthal.&Vis. Sci., 39(4):2236-B93 (S488) (1998).
Zifa et al., “5-Hydroxytryptamine Receptors,”Pharmaceutical Reviews, 44(3):401-548):1992.
Parker et al., “A Novel (Benzodifuranyl)aminoalkane with Extremely Potent Activity at the 5-HT2AReceptor,”J. Med. Chem., vol. 41, pp. 5148-5149 (1998).
English Abstract AN 1984:68106, RN#88745-48-6-P, 88745-49-7P, 88745-50-0, 88745-51-1P (Database CAPLUS on STN).
Alcon Inc.
Desai Rita
Ryan Patrick M.
LandOfFree
Aminoalkyl-benzofuran-5-ol compounds for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoalkyl-benzofuran-5-ol compounds for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoalkyl-benzofuran-5-ol compounds for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3632154